Real-world outcomes with tisagenlecleucel in aggressive B-cell lymphoma: subgroup analyses from the CIBMTR registry by Frederick L Locke, Grant Schofield, Marcelo Pasquini, Matthew J Frigault, Cameron J Turtle, Stephen Lim, Brian Hill, Samantha Jaglowski, Caron A Jacobson, Gunjan Shah, Daniel J Landsburg, Michael Heim, Stephen Ronan Foley, Ron Ram, Peter A Riedell, Leslie L Popplewell, Ranjan Tiwari, Marta Majdan, Aisha Masood

“…Background Tisagenlecleucel, a CD19 chimeric antigen receptor T-cell therapy, is approved for adults with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBCL) after ≥2 lines of therapy. …”
Get full text

<i>shp-2</i> gene knockout upregulates CAR-driven cytotoxicity of YT NK cells by V. G. Subrakova, S. V. Kulemzin, T. N. Belovezhets, A. N. Chikaev, N. A. Chikaev, O. A. Koval, A. A. Gorchakov, A. V. Taranin

“…These shp-2 knock-out NK cells were additionally transduced to express a chimeric antigen receptor (CAR) that selectively recognized the antigen of interest on the target cell surface and generated an activating signal. …”
Get full text

Structure-guided engineering of immunotherapies targeting TRBC1 and TRBC2 in T cell malignancies by Mathieu Ferrari, Matteo Righi, Vania Baldan, Patrycja Wawrzyniecka, Anna Bulek, Alexander Kinna, Biao Ma, Reyisa Bughda, Zulaikha Akbar, Saket Srivastava, Isaac Gannon, Mathew Robson, James Sillibourne, Ram Jha, Mohamed El-Kholy, Oliver Muhammad Amin, Evangelia Kokalaki, Mohammed Amin Banani, Rehan Hussain, William Day, Wen Chean Lim, Priyanka Ghongane, Jade R. Hopkins, Dennis Jungherz, Marco Herling, Martin Welin, Sachin Surade, Michael Dyson, John McCafferty, Derek Logan, Shaun Cordoba, Simon Thomas, Andrew Sewell, Paul Maciocia, Shimobi Onuoha, Martin Pule

“…This permits generation of paired reagents (chimeric antigen receptor-T cells) specific for TRBC1 and TRBC2, with preclinical evidence to support their efficacy in T cell malignancies.…”
Get full text

Selective JAK2 pathway inhibition enhances anti-leukemic functionality in CD19 CAR-T cells by Kohei Mitsuno, Masaya Suematsu, Yuki Naito, Azusa Mayumi, Hideki Yoshida, Shinya Osone, Toshihiko Imamura, Yozo Nakazawa, Shigeki Yagyu, Tomoko Iehara

“…Abstract The integration of molecular targeted therapeutics with chimeric antigen receptor T (CAR-T) cell therapy represents a novel strategy to amplify the anti-tumor efficacy of immunotherapy. …”
Get full text

The role of hospital pharmacists in supporting the appropriate and safe use of CGT/ATMPs: a scoping review of current insights by Junnan Shi, Xianwen Chen, Hao Hu, Carolina Oi Lam Ung

“…Of 26 studies, the perspectives assuming their roles in CGT/ATMPs management were categorized when patients receiving ATMPs (n = 2), HSCT and cellular-based therapy (n = 12), gene therapy (n = 6), and the chimeric antigen receptor (CAR) T-cell therapy (n = 6), mainly covering procurement, influences on prescribing, preparation and delivery, administration, monitoring of medicines use, human resources, training and development. …”
Get full text

PSCA-targeted BPX-601 CAR T cells with pharmacological activation by rimiducid in metastatic pancreatic and prostate cancer: a phase 1 dose escalation trial by Mark N. Stein, Ecaterina E. Dumbrava, Benjamin A. Teply, Usama S. Gergis, Martin E. Guiterrez, Ran Reshef, Sumit K. Subudhi, Céline F. Jacquemont, Joseph H. Senesac, J. Henri Bayle, Charity D. Scripture, Monica S. Chatwal, Mehmet A. Bilen, Walter M. Stadler, Carlos R. Becerra

“…These results suggest that pharmacological activation of GoCAR-T® cells is feasible and may offer a promising avenue to control chimeric antigen receptor-T cell activity with continued dose-optimization to improve tolerability.…”
Get full text

CAR T-cell detection scoping review: an essential biomarker in critical need of standardization by Naomi Taylor, Nirali N Shah, David P Turicek, Victoria M Giordani, Josquin Moraly

“…The expansion and persistence of chimeric antigen receptor (CAR) T-cells in patients are associated with response, toxicity, and long-term efficacy. …”
Get full text

Advances in CAR T cell therapy: antigen selection, modifications, and current trials for solid tumors by Safwaan H. Khan, Safwaan H. Khan, Yeonjoo Choi, Mysore Veena, Mysore Veena, John K. Lee, John K. Lee, Daniel Sanghoon Shin, Daniel Sanghoon Shin

“…Chimeric antigen receptor (CAR) T cell therapy has revolutionized the treatment of hematologic malignancies, achieving remarkable clinical success with FDA-approved therapies targeting CD19 and BCMA. …”
Get full text

Allogeneic CD33-directed CAR-NKT cells for the treatment of bone marrow-resident myeloid malignancies by Yan-Ruide Li, Ying Fang, Siyue Niu, Yichen Zhu, Yuning Chen, Zibai Lyu, Enbo Zhu, Yanxin Tian, Jie Huang, Valerie Rezek, Scott Kitchen, Tzung Hsiai, Jin J. Zhou, Pin Wang, Wanxing Chai-Ho, Sunmin Park, Christopher S. Seet, Caspian Oliai, Lili Yang

“…Abstract Chimeric antigen receptor (CAR)-engineered T cell therapy holds promise for treating myeloid malignancies, but challenges remain in bone marrow (BM) infiltration and targeting BM-resident malignant cells. …”
Get full text

Pseudoprogression in CAR-T cell therapy for solid tumor: Case report by Xuan Zhao, Xuan Zhao, Yanfen Liu, Yanfen Liu, Guohui Qin, Guohui Qin, Yan Ge, Qinglong Li, Xinfeng Chen, Xinfeng Chen, Ximei Tian, Yong Yu, Jiangtao Ren, Yi Zhang, Yi Zhang, Yi Zhang, Yi Zhang, Yi Zhang

“…We reported the pseudoprogression in an elderly patient with advanced gastric cancer after chimeric antigen receptor (CAR)-T cell therapy. The hepatic metastases enlarged 1 month after CAR-T cell infusion and then shrunk the next month as seen through computed tomography scanning. …”
Get full text

Safety and efficacy of anti-CD30 CAR-T cell therapy in relapsed/refractory classic Hodgkin lymphoma: a systematic review and meta-analysis by Fanqiao Meng, Maoyuan Xiang, Yu Liu, Dongfeng Zeng

“…Abstract Background Relapsed/refractory classic Hodgkin lymphoma (R/R cHL) remains challenging to treat, and anti-CD30 chimeric antigen receptor T (CAR-T) cell therapy may be effective. …”
Get full text

Loading monocytes with magnetic nanoparticles enables their magnetic control without toxicity by Laura Mödl, Laura Mödl, Lucas R. Carnell, Rene Stein, Andrea Kerpes, Felix Pfister, Barbara Wirthl, Wolfgang A. Wall, Christoph Alexiou, Christina Janko

“…., for immunotherapy with chimeric antigen receptor (CAR) monocytes. Here, we investigated the loading of monocytic THP-1 cells with SPIONs, analyzed their impact on the viability and cellular reactive oxygen species (ROS) generation and their magnetic enrichment. …”
Get full text

Art of TIL immunotherapy: SITC’s perspective on demystifying a complex treatment by Robert Brown, Marco Donia, Simon Turcotte, George Coukos, John Mullinax, Brian Gastman, James C Yang, Michael T Lotze, John B A G Haanen, Inge Marie Svane, Stephanie L Goff, Vernon K Sondak, Maartje W Rohaan, Michal Besser, Benjamin Creelan

“…Since the advent of chimeric antigen receptor (CAR) T cells for patients with hematological malignancies, a growing network of centers capable of delivering effector T cell products to patients has developed. …”
Get full text

Preclinical optimization of a GPC2-targeting CAR T-cell therapy for neuroblastoma by Nan Li, Haiying Qin, Rosa Nguyen, Mitchell Ho, Ming Sun, Eytan Ruppin, Michael C Kelly, Yingying Cao, Reona Okada, Jeyshka M Reyes-González, Hannah G Stack, Charlie Seibert, Carol J Thiele

“…We developed a new chimeric antigen receptor (CAR) targeting glypican-2 (GPC2) and conducted iterative preclinical engineering of the CAR structure to maximize its anti-tumor efficacy before clinical translation.Methods We evaluated different GPC2-CAR constructs by measuring the CAR activity in vitro. …”
Get full text

Loss of p53 impairs death receptor expression and confers resistance to CD19 CAR T-cell therapy in BCP-ALL by Willem P. J. Cox, Noël M. M. Dautzenberg, Linde Dekker, Tesa Klenovsek, Annelisa M. Cornel, Marliek van Hoesel, Dorette S. van Ingen Schenau, Reno S. Bladergroen, Roland P. Kuiper, Laurens T. van der Meer, Friso G. Calkoen, Stefan Nierkens, Frank N. van Leeuwen

“…Abstract: Loss of p53 function predicts a dismal outcome in relapsed B-cell precursor acute lymphoblastic leukemia (BCP-ALL). Chimeric antigen receptor T-cell (CAR T) therapy was recently approved to salvage relapsed/refractory BCP-ALL. …”
Get full text

Efficacy and Safety of CART Cell Therapy in Aggressive B‐Cell Lymphomas Involving the Gastrointestinal Tract by Lixia Ma, Yimeng Dou, Rui Liu, Teng Xu, Fan Yang, Peihao Zheng, Shaomei Feng, Yuelu Guo, Hui Shi, Fei Xue, Biping Deng, Xiaoyan Ke, Kai Hu

“…ABSTRACT Objective Currently, chimeric antigen receptor T‐cell (CART) therapy represents a highly effective approach for relapsed/refractory B‐cell lymphomas. …”
Get full text

CD93 blockade promotes effector T-cell infiltration and facilitates adoptive cell therapy in solid tumors by Yi Sun, Eduardo Davila, YuJie Guo, Richard D Schulick, Elliott Yee, Yuki Fujiwara, Kaitlyn Dickinson, Zhiwei Sun, Junyi Hu, Yuwen Zhu

“…Background Adaptive cellular therapy (ACT), particularly chimeric antigen receptor (CAR)-T cell therapy, has been successful in the treatment of hemopoietic malignancies. …”
Get full text

Engineering of SauriCas9 with enhanced specificity by Xiaoqi Zhang, Chen Tao, Miaomiao Li, Sufang Zhang, Puping Liang, Yan Huang, Huihui Liu, Yongming Wang

“…To validate its efficacy, we employed SauriCas9-R253A to disrupt three genes (B2M, TRAC, and PDCD1), a strategy integral to the development of allogeneic chimeric antigen receptor T cell (CAR-T) therapies. Our results demonstrated that the most efficient single-guide RNAs for SauriCas9-R253A exhibited comparable activity to SpCas9 and showed no detectable off-target effects in the disruption of these genes, highlighting its therapeutic potential.…”
Get full text

Mesenchymal Stem Cells Carrying Viral Fusogenic Protein p14 to Treat Solid Tumors by Inducing Cell–Cell Fusion and Immune Activation by Yao Wang, Xunlei Pang, Ruirui Li, Jiuzhou Chen, Chen Wen, Huihuang Zhu, Tingyu Long, Jianjie Li, Lijun Zheng, Youcai Deng, Junnian Zheng, Bo Xu

“…Background: Chimeric antigen receptor (CAR)-based immune cell therapies attack neighboring cancer cells after receptor recognition but are unable to directly affect distant tumor cells. …”
Get full text

Clinically relevant orthotopic pancreatic cancer models for adoptive T cell transfer therapy by Gregory B. Lesinski, Chrystal M. Paulos, Maggie Phillips, Jacklyn Hammons, Isaac Karpovsky, Zaid Mahdi, Natalie K. Horvat, Megan M. Wyatt, Margaret A. Hall, Cameron J. Herting, Richard A. Moffitt

“…Interestingly, we found that chimeric antigen receptor (CAR) T cells redirected to recognize mesothelin on these tumors that signal via CD3ζ and 41BB (Meso-41BBζ-CAR T cells) infiltrated the tumors of mice bearing stroma-devoid KPC-Luc orthotopic tumors, but not MT-5 tumors.Conclusions Our data establish for the first time a reproducible and realistic clinical system useful for modeling stroma-rich and stroma-devoid PDAC tumors. …”
Get full text